Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.35 |
| ▸ | PRKCG | P05129 | 3/20 | 0.35 |
| ▸ | PRKCB | P05771 | 3/20 | 0.35 |
| ▸ | PRKCA | P17252 | 3/20 | 0.35 |
| ▸ | PRKCH | P24723 | 3/20 | 0.35 |
| ▸ | PRKCI | P41743 | 3/20 | 0.35 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.35 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.34 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508770 | 0.98 | ZDHHC7 (0.38) | OPRM1ZDHHC7PRKD3PRKCGPRKCB | |
| SCHEMBL8933419 | 0.98 | ZDHHC7 (0.38) | OPRM1ZDHHC7PRKD3PRKCGPRKCB | |
| SCHEMBL7439501 | 0.98 | ZDHHC7 (0.38) | OPRM1ZDHHC7PRKD3PRKCGPRKCB | |
| SCHEMBL386111 | 0.98 | ZDHHC7 (0.38) | OPRM1ZDHHC7PRKD3PRKCGPRKCB | |
| SCHEMBL7194789 | 0.98 | ZDHHC7 (0.38) | OPRM1ZDHHC7PRKD3PRKCGPRKCB | |
| SCHEMBL385914 | 0.93 | — | — | |
| SCHEMBL28571242 | 0.88 | OPRM1 (0.34) | OPRM1ZDHHC7PRKD3PRKCGPRKCB | |
| SCHEMBL5316573 | 0.84 | OPRM1 (0.36) | OPRM1ZDHHC7PRKD3PRKCGPRKCB | |
| SCHEMBL13464149 | 0.82 | TSHR (0.44) | OPRM1ZDHHC7PRKD3PRKCGPRKCB | |
| SCHEMBL14520047 | 0.82 | TSHR (0.44) | OPRM1ZDHHC7PRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635839-B1 | BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2010-09-01 | — | — | EP | claimed |
| US-7524853-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-04-28 | — | — | US | claimed |
| US-7465739-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-12-16 | — | — | US | claimed |
| WO-2007068352-A1 | A USE OF BARBITURIC ACID DERIVATIVES AS HERBICIDAL EFFICACY-ENHANCING AGENTS OR HERBICIDAL AGENTS AND PROCESS FOR THEIR PREPARATION | BAYER CROPSCIENCE AG (DE) | 2007-06-21 | — | — | WO | claimed |
| EP-1635839-A2 | BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | Solvay Pharmaceuticals B.V. (NL) | 2006-03-22 | — | — | EP | claimed |
| US-20050176742-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-08-11 | — | — | US | claimed |
| WO-2005032527-A2 | BENZO (4, 5) THIENO (2, 3-D) PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-04-14 | — | — | WO | claimed |
| US-20050038053-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-17 | — | — | US | claimed |
| EP-1655291-B1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO (JP) | 2016-08-03 | — | — | EP | disclosed |
| CN-103130739-B | There is the compound of thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2015-09-16 | — | — | CN | disclosed |
| CN-102796058-B | Compound having thrombopoietin receptor agonism | SHIONOGI & CO | 2015-05-13 | — | — | CN | disclosed |
| US-8101650-B2 | Method for treating a immunology-related disease | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-24 | — | — | US | disclosed |
| CN-102271732-A | Nanochannel devices and related methods | — | 2011-12-07 | — | — | CN | disclosed |
| US-8067396-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| EP-1384504-A2 | Methods for producing ligand arrays | Agilent Technologies, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030236297-A1 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-1300405-A1 | AMINO ALCOHOL DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-4099014-A | BLOOD PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
| US-4033989-A | 9-Deoxy-PGF2 Analogs | THE UPJOHN COMPANY (US) | 1977-07-05 | — | — | US | disclosed |
| US-4016184-A | PROSTAGLANDINS, BLOOD PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236297-A1 | Amino alcohol derivatives | CD4, ADH1C, ADH1A | OPRM1 163/4885ZDHHC7 1680/4885PRKD3 1822/4885 |
| US-20050176742-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | OPRM1 2720/4885ZDHHC7 800/4885PRKD3 740/4885 |
| US-20050038053-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | OPRM1 2720/4885ZDHHC7 800/4885PRKD3 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.